Non-Hodgkin Lymphoma | Specialty

Treating Follicular Lymphoma With Early Progression

April 5th 2021

Approaches to sequencing therapy for patients with follicular lymphoma who experience progression of disease within 24 months (POD24).

Emerging Therapies for R/R Follicular Lymphoma

April 5th 2021

An overview of novel therapies under investigation for the treatment of relapsed/refractory follicular lymphoma and special considerations regarding treating patients with newer, novel agents in the community setting.

Dr. D’Angelo on the Potential Drawbacks of 5-Drug Combinations in B-Cell Lymphoma

April 2nd 2021

Christopher R. D’Angelo, MD, discusses the potential drawbacks of 5-drug combinations in B-cell lymphoma.

Simplified Geriatric Assessment Validated as OS Predictor in Elderly Patients With DLBCL

April 2nd 2021

A simplified geriatric assessment offers a validated objective tool to assess fitness status and should be considered the new Elderly Prognostic Index standard to predict overall survival in older patients with diffuse large B-cell lymphoma.

Duvelisib Granted Positive EU Opinion for Relapsed/Refractory CLL and Refractory Follicular Lymphoma

April 1st 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of single-agent duvelisib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia following at least 2 prior therapies, and follicular lymphoma that is refractory to at least 2 prior systemic treatments.

Third-Line CAR T-Cell Therapy Improves Outcomes in B-Cell Lymphomas

April 1st 2021

CAR T-cell therapies are now incorporated into National Comprehensive Cancer Network guidelines as a recommended third-line strategy in this setting, with the most recent addition being lisocabtagene maraleucel.

Liso-Cel Approved in Japan for Relapsed/Refractory Large B-Cell Lymphoma

March 29th 2021

Japan’s Ministry of Health, Labour and Welfare has approved lisocabtagene maraleucel, a CAR T-cell therapy designed to target CD19, for the treatment of patients with relapsed or refractory large B-cell lymphoma, as well as relapsed/refractory follicular lymphoma.

Rolling Submission of BLA to FDA Completed for Ublituximab/Umbralisib in CLL

March 29th 2021

The rolling submission of a biologics license application to support the approval of ublituximab plus umbralisib as a treatment for patients with chronic lymphocytic leukemia has been completed.

Case Discussion: 68-Year-Old With R/R Follicular Lymphoma

March 29th 2021

A panel of hematologist-oncologists share best practices for managing a 68-year-old male with relapsed/refractory follicular lymphoma who is under consideration for treatment with tazemetostat.

R/R Follicular Lymphoma: Testing for EZH2

March 29th 2021

Andrew M. Evens, DO, MSc, FACP, of Rutgers Cancer Institute of New Jersey, comments on the rationale for testing for EZH2 mutations in relapsed/refractory follicular lymphoma.

Evolving Therapies in R/R DLBCL: Concluding Remarks

March 26th 2021

R/R DLBCL: A Glance at Using Novel Therapies Moving Forward

March 26th 2021

R/R DLBCL: Novel Therapies in the Pipeline

March 26th 2021

EZH2 Inhibition in R/R FL: Safety & Efficacy Data

March 22nd 2021

Takeaways of safety and efficacy data published on tazemetostat, an EZH2 inhibitor, to treat relapsed/refractory follicular lymphoma, and implications for using the drug in clinical practice.

Tazemetostat for R/R Follicular Lymphoma

March 22nd 2021

Drs Andrew M. Evens and Loretta J. Nastoupil remark on the recent approval of tazemetostat, an EZH2 inhibitor, as treatment for relapsed/refractory follicular lymphoma and highlight which types of patients are most appropriate to manage with this drug.

Treating Primary Refractory DLBCL

March 19th 2021

Bridging Therapy in R/R DLBCL

March 19th 2021

Real-World Data Showcase Favorable Outcomes and Less Toxicity With Axi-Cel in Large B-Cell Lymphoma

March 17th 2021

The real-world utilization of axicabtagene ciloleucel demonstrated favorable outcomes and less frequent toxicity events compared with those reported in the pivotal ZUMA-1 trial and other real-world studies.

R2 Regimen for R/R Follicular Lymphoma

March 15th 2021

An overview of the MAGNIFY data and implications for treating appropriate patients with relapsed/refractory follicular lymphoma with the R2 regimen.

PI3K Inhibitors for R/R Follicular Lymphoma

March 15th 2021

Recommendations for treating patients with relapsed/refractory follicular lymphoma with an available PI3K inhibitor and managing adverse events from treatment.